We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

One third of antimalarial drugs sold in six African cities have failed quality tests, signalling the need to tighten post-market regulation and surveillance of drugs.

Researchers found that antimalarials in cities in Ghana, Kenya, Nigeria, Rwanda, Tanzania and Uganda failed the basic quality tests.

Their study also found that therapies such as artemisinin monotherapies — rejected by the WHO as substandard — remain prevalent in Africa. A third of the drugs tested in the study were monotherapies, and 42 per cent of them failed basic quality tests.

Substandard drugs accelerate drug resistance in malaria parasites, jeopardising future malaria treatment strategies, says Roger Bate, resident fellow at the American Enterprise Institute and lead author of the study.

The researchers recommend that a fraction of the current global budget for malaria control should be put toward a decentralised network for quality control using technologies such as mini-labs and portable testing kits.

The study was published in PLoS ONE last week (6 May).

Link to full article in Health-e

Link to full paper in PLoS ONE



PLoS ONE doi 10.1371/journal.pone.0002132 (2008)